The Ben Towne Center has adopted a unique approach that combines academic research with elements of a biotech firm. This approach, combined with our emphasis on collaboration, enables our investigators to carry discoveries and innovations from the research bench to the pediatric oncology clinic.
Applying Immunology to Oncology
Our primary area of research is immunotherapy, which activates the immune system to treat diseases. Immunotherapy has quickly advanced from early attempts of simply injecting cytokines - molecules that help control cellular immune response - into patients, to engineering DNA that incorporates into T cells. Each step has increased safety and improved outcomes, and the Ben Towne Center is speeding up the process of treating patients.
This is based largely on our rapidly increasing understanding of the way T cells interact with cancer cells, combined with the role of balancing cytokines and T cells in specific ratios. We are building a library of engineered, tumor-specific T-cell receptors with exacting cellular interaction characteristics. This T-cell receptor specificity is what lets a T cell recognize and attach to a tumor cell, without attacking anything else in the body.
These cellular interactions may be different for each type of cancer. There is also a difference between how CD4+ and CD8+ T cells interact with tumor antigens. We are investigating those differences to further refine our clinical approach.
Our immunology work also explores how to ensure that patients tolerate transplanted immune cells and avoid graft versus host disease. This is essential to expanding our treatment approach to the broadest possible population.
Merging Academic Research with a Biotech Infrastructure
The Ben Towne Center has assembled an infrastructure to drive the next era of cancer immunotherapy development. This infrastructure includes:
New Cure. New Hope.
Through our Strong Against Cancer initiative, we’re leading the fight against childhood cancer with new immunotherapy treatments. Our recent clinical trial for acute lymphoblastic leukemia (ALL) resulted in a 91% complete remission rate in children with relapsed leukemia.